Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Inclusion Criteria: * Requires hospitalization for COVID-19 infection * Has Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) test before study entry * Requires supplemental oxygen for pulmonary distress related to COVID-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less * Has radiographic evidence of pulmonary infiltrates * Females of childbearing potential (FCBP) must use 1 reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test as of screening. * Men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a FCBP. * Adequate hematologic, hepatic and renal function as described in the protocol * Must be within 10 days of confirmed diagnosis of COVID-19 Exclusion Criteria: * Respiratory failure at time of screening as defined per protocol with any of these following therapies: * Endotracheal intubation and mechanical ventilation * Extracorporeal membrane oxygenation (ECMO) * High flow nasal cannula ox…